Creative Medical Technology Holdings Inc represents a commitment to innovation, excellence, and patient-centric healthcare. With a strong corporate philosophy focused on improving medical outcomes, Creative Medical Technology Holdings Inc aims to revolutionize the field of regenerative medicine. The company is dedicated to developing cutting-edge technologies and therapies that address the unmet needs of patients worldwide. By harnessing the power of stem cells and other advanced biological materials, Creative Medical Technology Holdings Inc strives to provide effective solutions for various medical conditions, promoting a healthier and better quality of life for individuals.

Creative Medical Technology Holdings Inc is primarily present in the United States of America.

Creative Medical Technology Holdings Inc has achieved significant milestones in their journey. The company has successfully developed innovative regenerative medical technologies and secured multiple patents in various fields, including reproductive medicine, immunology, and stem cell therapies. Additionally, Creative Medical Technology Holdings Inc has conducted successful clinical trials and collaborations with renowned medical institutions, further solidifying their position as a leading player in the regenerative medicine industry. The company's dedication to research and development, combined with their fruitful partnerships, has contributed to their notable achievements in advancing medical treatments and addressing unmet medical needs.

Creative Medical Technology Holdings Inc is a leading biotechnology company specializing in regenerative medicine. Established in [year], the company has a rich history of innovation and breakthroughs in the field. With a team of experienced scientists and researchers, Creative Medical Technology Holdings Inc focuses on developing cutting-edge therapies and treatments for various medical conditions. The company's commitment to improving patient outcomes through regenerative medicine has earned it a strong reputation in the industry. Leveraging its expertise and advanced technologies, Creative Medical Technology Holdings Inc continues to drive advancements in regenerative medicine, positioning itself as a leader in the field.

The main competitors of Creative Medical Technology Holdings Inc in the market include companies such as Johnson & Johnson, Medtronic, Inc., Boston Scientific Corporation, Abbott Laboratories, and Stryker Corporation.

Creative Medical Technology Holdings Inc is primarily active in the healthcare industry.

Creative Medical Technology Holdings Inc., a leading biotechnology company, focuses on developing innovative solutions in regenerative medicine. The company's business model revolves around identifying, acquiring, and advancing breakthrough technologies, aiming to improve patient outcomes and quality of life. With a strong emphasis on research and development, Creative Medical Technology Holdings Inc. collaborates with renowned experts and institutions in the field of regenerative medicine to bring cutting-edge therapeutic options to market. By harnessing the power of stem cells and other novel approaches, the company is dedicated to tackling some of the most challenging medical conditions and providing hope for patients worldwide.

Коефициентът на цена спрямо печалбата (КЦП) на Creative Medical Technology Holdings е -0,09.

Коефициентът на цена към оборот (KUV) на Creative Medical Technology Holdings е 0.

AlleAktien качественият резултат за Creative Medical Technology Holdings е 4/10.

Приходите не могат да бъдат изчислени в момента за Creative Medical Technology Holdings.

очаквана Creative Medical Technology Holdings печалба е -47,22 млн. USD.

Creative Medical Technology Holdings Inc. (CMT) is a biological research company that focuses on innovative biotechnological solutions for unmet medical needs. The company is divided into several divisions that oversee different product lines and research projects. The main divisions of CMT are Regenerative Medicine, Stem Cell Research, Urology, and Oncology. The Regenerative Medicine division is CMT's flagship and focuses on researching and developing cellular therapies for tissue and organ restoration. An example of the product portfolio in this division is AmnioStem, a stem cell therapy derived from human placenta extract that can be used to support tissue regeneration. CMT's Stem Cell Research department utilizes innovative technologies to isolate, cultivate, and differentiate stem cells for medical research and therapy development. An example of the product portfolio in this division is Xenostem, a method for reprogramming pig stem cells for human use. CMT's Urology division specializes in developing products that facilitate the treatment of urinary tract and male reproductive system disorders. An example of the product portfolio in this division is ImmCelz, a product for modulating immunotherapy in patients with chronic interstitial cystitis. CMT's Oncology division specializes in researching new drugs for cancer treatment. An example of the product portfolio in this division is CMTC-Oncology, an innovative cancer drug derived from a plant extract. CMT collaborates closely with academic institutions and clinics to validate its research findings in preclinical and clinical trials. CMT's products are designed to meet the medical needs of people worldwide. CMT's business model is to leverage innovative technologies for developing therapies for unmet medical needs and market these therapies through licensing agreements or partnerships with pharmaceutical or biotechnology companies. CMT also works on developing its own medical products that are launched on the market through its own distribution network or partner companies. CMT also employs an aggressive IP strategy to ensure the protection of intellectual property rights for its products and technologies. This gives the company a clear competitive position in the market. CMT's goal is to make a significant contribution to improving the health and well-being of people worldwide by developing innovative biotechnological solutions for unmet medical needs.

Creative Medical Technology Holdings разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Creative Medical Technology Holdings в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Creative Medical Technology Holdings е US22529Y2000.

WKN на Creative Medical Technology Holdings е A2PZE4.

Тикерът на Creative Medical Technology Holdings е CELZ.

През последните 12 месеца Creative Medical Technology Holdings изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Creative Medical Technology Holdings да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Creative Medical Technology Holdings в момента е .

Creative Medical Technology Holdings изплаща дивидент на тримесечие. Той се разпределя в месеците .

Creative Medical Technology Holdings платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Creative Medical Technology Holdings се отнася за сектор '—'.

За да получите последното дивидентно плащане от Creative Medical Technology Holdings на 2.10.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 2.10.2024 г..

Последното дивидентно плащане беше извършено на 2.10.2024 г..

През година 2023 Creative Medical Technology Holdings изплати 0 USD под формата на дивиденти.

Дивидентите от Creative Medical Technology Holdings се изплащат в USD.